Transparency, rigor, and patient-centered research across our therapeutic portfolio. All active and completed trials are registered with FDA, EMA, and ClinicalTrials.gov.
| Trial ID | Title & Condition | Phase | Status | Enrollment | Details |
|---|---|---|---|---|---|
| ZEP-2025-0042 |
ZENTH-ONCO-A3 in Advanced Solid Tumors
Oncology · Target: EGFR/ALK Inhibitors
|
Phase III | Recruiting |
426 / 625
|
View Protocol → |
| ZEP-2025-0038 |
NeuroZenth 7b for Mild Cognitive Impairment
Neurology · Target: Amyloid-β / Tau
|
Phase II | Recruiting |
89 / 260
|
View Protocol → |
| ZEP-2024-0089 |
CardioZenth-1 in Heart Failure with Reduced EF
Cardiovascular · Target: SGLT2 Modulation
|
Phase III | Active |
1,150 / 1,250
|
View Protocol → |
| ZEP-2025-0051 |
ImmunoZenth 4a for Rheumatoid Arthritis
Autoimmune · Target: IL-6 / TNF-α Biologic
|
Phase I | Recruiting |
12 / 66
|
View Protocol → |
| ZEP-2023-0022 |
MetaZenth-Endo in Type 2 Diabetes Management
Metabolic · Target: GLP-1/GIP Dual Agonist
|
Phase IV | Completed |
2,100 / 2,100
|
View Results → |
| ZEP-2024-0067 |
ZENTH-ONCO-B1 for Pancreatic Adenocarcinoma
Oncology · Target: CAR-T / Checkpoint Inhibitor
|
Phase II | Paused |
68 / 150
|
View Status → |
All trials receive full Institutional Review Board and Ethics Committee approval prior to initiation. Patient safety and informed consent are our highest priorities.
Results are published within 12 months of trial completion. Full datasets, protocols, and adverse event reporting are available through clinicaltrials.gov and EU-CTR.
Zenth Pharma adheres to ICH-GCP guidelines, FDA 21 CFR Parts 11/50/54, EMA guidelines, and local regulatory frameworks across all operational regions.
Our trials incorporate patient advisory boards, decentralized clinical trial (DCT) capabilities, and real-world evidence integration to reduce burden and improve outcomes.
Whether you're a patient seeking cutting-edge treatments, a site looking to host a trial, or a healthcare provider with questions, our research team is here to help.